Company Executives of Drugs Made In America Acquisition II Units
Name
Name/Position
Position
Shareholding
Change
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
FAQs
Who are the top five shareholders of Drugs Made In America Acquisition II Units?
The top five shareholders of Drugs Made In America Acquisition II Units are: Ms. Lynn Stockwell
How many institutions hold shares of Drugs Made In America Acquisition II Units (DMIIU)?
As of 2026Q1, 86 institutions hold shares of Drugs Made In America Acquisition II Units, with a combined market value of approximately 11.63M, accounting for 17.74% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -34872876.00.